EU

Life Sciences M&A in a holding pattern

Matthew Appleton

Continued uncertainty surrounding President Trump’s proposed tax reforms has slowed activity in the Life Sciences sector, with deal values holding well below the record levels seen in previous years. If Trump’s promised corporate tax cut materialises, big U.S. players may be encouraged to repatriate (and spend) the huge amounts of cash currently held offshore.  But Read More

European Commission assesses bids for the relocation of the European Medicines Agency

Jacqueline Bore

On Saturday, the European Commission (EC) published its assessment of the bids by 19 Member States to host the European Medicines Agency (EMA) when it relocates from London in March 2019. As instructed by the Member States, the EC has been careful to avoid betraying any preference by producing a ranking or short list. The Read More

European and UK medical device industry bodies urge post-Brexit regulatory alignment

William Palmer

In a joint letter to the negotiators representing the UK and EU, medical device and in vitro diagnostic industry trade groups have urged both parties to ensure full regulatory implementation in their sector following “Brexit”, in March 2019.  The trade groups represented are MedTech Europe (MedTech), the Association of British Healthcare Industries (ABHI) and the Read More

The definition of “product” in the SPC Regulation: (Part 1 of 2) What’s in a name?

Nicola Dagg

Anyone familiar with supplementary protection certificate (SPC) law will know the importance of the definition of “product” for SPC purposes. “Product” is defined within art.1(b) of Regulation (EC) No 469/2009 (the SPC Regulation) and plays a central role in the interpretation of that Regulation, in particular as regards the conditions for obtaining an SPC set Read More

EU sets out its position in Brexit negotiations on Intellectual Property Rights (including geographical indications)

Erin Currie

On 7 September 2017, the EU released a number of Brexit negotiation position papers, including one regarding Intellectual property rights which is of significant importance to the IP intensive Life Sciences industry.  The paper sets out the position of the EU27 on existing Intellectual Property (“IP”) rights and the exhaustion of those rights at the withdrawal date.  Read More